BeiGene

We’re proud to share Vizient, Inc has recognized BeiGene with the 2024 Pharmacy Strategic Excellence Award! This award highlights the success and commitment of our Market Access team in empowering Vizient provider customers to optimize cost, quality and market performance to ultimately improve healthcare for patients. Learn more: https://bit.ly/4dx4maD

#News for #Investors and #Media: BeiGene announces availability of our PD-1 inhibitor in the U.S. for eligible patients with esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. Learn more about our commitment to bringing this important therapy to patients.  https://bit.ly/4dA8I0T

#LungCancer is the most common cancer diagnosed globally, which is why we continue to advance our research in this area. Data from a Phase 3 study of our PD-1 inhibitor in advanced squamous NSCLC was recently published in ESMO Open (a journal from ESMO - European Society for Medical Oncology) highlighting long-term follow-up results. Learn more: https://bit.ly/4ezbzIM

#News for #Investors and #Media: Our innovative PD-1 inhibitor has been approved in Singapore for the treatment of esophageal squamous cell carcinoma (ESCC) as a second-line therapy and non-small cell lung cancer (NSCLC) in the frontline or second-line setting. #ESCC #NSCLC #ImmunoTherapy

Worldwide there are an estimated 1.8 million new cases of non-small cell lung cancer (NSCLC) each year and BeiGene continues to share new research for this patient population. New research published in ESMO Open (a journal from ESMO - European Society for Medical Oncology) highlights results from the final analysis of a Phase 3 study evaluating our PD-1 inhibitor in patients with advanced nonsquamous NSCLC. Read the research here: https://bit.ly/3TSmYLs

#News for #Investors and #Media: Our BTK Inhibitor has received approval in the Philippines for the treatment of chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). This approval marks the fourth indication of our treatment for blood cancer in the country. #CLL #MZL #BloodCancer

Mark Lanasa, our CMO of Solid Tumors, joined industry peers this week at the Fierce Biotech Summit where he shared the rationale behind how our expansive pipeline supports our mission to develop more accessible and affordable cancer medicines. #FierceBiotechSummit 

I was thrilled to join the panel, "Building a Culture of Sustainability in Pharma" at BioWeek Boston with James Connelly, Byron Austin and Manu Juneja. We tackled key issues such as avoiding greenwashing, the importance of third-party verification, and the challenges of sustainable practices in pharma and biotech. At BeiGene, we recognize that human health and the health of the planet are intrinsically linked, and we are committed to mitigating our environmental impacts. With the health sector generating 4-5% of global emissions, it’s clear we must work together to create a greener future through sustainable innovation and collaboration. #Sustainability #Pharma #Biotech #ESG

We’re honored to be awarded the 2024 Corporate Leadership Award from the Lymphoma Research Foundation at their Annual Gala in New York City. This recognition highlights our commitment to advancing bold cancer research, developing next-generation therapies, and supporting patients with medicines that are both affordable and accessible worldwide. Thank you to the Foundation for this accolade. We are grateful to work alongside you to bring more hope and better outcomes to patients with lymphoma. Read more here: https://bit.ly/3N9dKGL #PatientsFirst #Lymphoma

Did you know 1 in 8 women in the U.S. will develop breast cancer in her lifetime? It is the second leading cause of cancer death among women in the country.   We believe awareness is key to empowering individuals to make informed health decisions. Breast Cancer Awareness Month serves as an opportunity to honor those affected by this disease and to reflect on the latest advancements in research, prevention, and treatment. Let’s come together to spread knowledge and support one another! #BreastCancerAwarenessMonth